Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06390410 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function
A Phase 1 study, sponsored by Cassava Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT06390410 is a Phase 1 study that has completed, run by Cassava Sciences. The registered enrollment target is 27 participants.
The verdict
NCT06390410, a Phase 1 study, has completed, sponsored by Cassava Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
Evaluate simufilam levels in the blood of hepatically impaired individuals compared to Healthy individuals of similar demographics
Interventions
- DRUG Simufilam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2024-06-26 |
| Est. Completion | 2024-12-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06390410
The ClinicalTrials.gov registry entry for NCT06390410 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cassava Sciences, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Simufilam is the first listed.
NCT06390410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06390410 about?
NCT06390410 is a clinical study titled "A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function". Evaluate simufilam levels in the blood of hepatically impaired individuals compared to Healthy individuals of similar demographics
What is the current status of trial NCT06390410?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2024-06-26. Estimated completion is 2024-12-07.
What interventions are being tested in trial NCT06390410?
The interventions under investigation include: Simufilam (DRUG).
Who is sponsoring clinical trial NCT06390410?
This trial is sponsored by Cassava Sciences, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.